论文部分内容阅读
报告自体骨髓移植治疗白血病３９例，其中非净化自体骨髓移植（ＡＢＭＴ）１４例，净化自体骨髓移植（ＰＡＢＭＴ）２５例。中位年龄２８岁（１０～４３岁）。ＡＭＬ２７例，ＡＬＬ１０例，ＣＭＬ２例。ＣＲ１３１例，ＣＲ２７例，ＮＲ１例。ＣＲ至移植时间中位数６．７个月（２～１９个月）。预处理方案：ＴＢＩ加Ａｒａ－ｃ、ＤＮＲ或ＶＰ１６。ＡＢＭＴ组及ＰＡＢＭＴ组３年无病生存（ＤＦＳ）率分别为６８．３２％及６７．５７％，复发率为３０．７６％及２６．８０％。但ＰＡＢＭＴ组ＡＭＬ患者３年ＤＦＳ率为８２．３５％及ＣＲ２期移７５％３年ＤＦＳ率为７５％，明显高于ＣＲ。期移植未净化者５０％。化疗组３年ＤＦＳ率为７．３８％及复发率７６．４％，两移植组疗效优于化疗组。
Reports 39 cases of leukemia treated with autologous bone marrow transplantation, including 14 cases of uncleaned autologous bone marrow transplantation (ABMT) and 25 cases of autologous bone marrow transplantation (PABMT). The median age is 28 years (10 to 43 years old). There were 27 cases of AML, 10 cases of ALL, and 2 cases of CML. CR 131 cases, CR 27 cases, NR 1 cases. The median time from CR to transplantation was 6.7 months (2 to 19 months). Pretreatment plan: TBI plus Ara-c, DNR, or VP16. The 3-year disease-free survival (DFS) rates in the ABMT and PABMT groups were 68.32% and 67.57%, respectively, and the recurrence rates were 30.76% and 26.80%. However, the 3-year DFS rate in patients with AML in the PABMT group was 82.35% and the CR2 shift was 75%. The 3-year DFS rate was 75%, which was significantly higher than CR. Transplanted untreated 50%. The 3-year DFS rate in the chemotherapy group was 7.38% and the recurrence rate was 76.4%. The efficacy of the two-transplantation group was better than that of the chemotherapy group.